Last reviewed · How we verify

Dolutegravir film-coated tablets

ViiV Healthcare · Phase 3 active Small molecule

Dolutegravir film-coated tablets is a Integrase strand transfer inhibitor (INSTI) Small molecule drug developed by ViiV Healthcare. It is currently in Phase 3 development for HIV-1 infection in treatment-naïve adults, HIV-1 infection in treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).

Dolutegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.

Dolutegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-naïve adults, HIV-1 infection in treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).

At a glance

Generic nameDolutegravir film-coated tablets
SponsorViiV Healthcare
Drug classIntegrase strand transfer inhibitor (INSTI)
TargetHIV integrase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Dolutegravir is an integrase strand transfer inhibitor (INSTI) that binds to HIV integrase and blocks the enzyme's ability to catalyze the integration of viral DNA into the human genome. By preventing this critical step in the HIV replication cycle, the drug stops viral propagation and reduces viral load in infected individuals. This mechanism allows for effective suppression of HIV replication with a high genetic barrier to resistance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dolutegravir film-coated tablets

What is Dolutegravir film-coated tablets?

Dolutegravir film-coated tablets is a Integrase strand transfer inhibitor (INSTI) drug developed by ViiV Healthcare, indicated for HIV-1 infection in treatment-naïve adults, HIV-1 infection in treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).

How does Dolutegravir film-coated tablets work?

Dolutegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.

What is Dolutegravir film-coated tablets used for?

Dolutegravir film-coated tablets is indicated for HIV-1 infection in treatment-naïve adults, HIV-1 infection in treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).

Who makes Dolutegravir film-coated tablets?

Dolutegravir film-coated tablets is developed by ViiV Healthcare (see full ViiV Healthcare pipeline at /company/viiv-healthcare).

What drug class is Dolutegravir film-coated tablets in?

Dolutegravir film-coated tablets belongs to the Integrase strand transfer inhibitor (INSTI) class. See all Integrase strand transfer inhibitor (INSTI) drugs at /class/integrase-strand-transfer-inhibitor-insti.

What development phase is Dolutegravir film-coated tablets in?

Dolutegravir film-coated tablets is in Phase 3.

What are the side effects of Dolutegravir film-coated tablets?

Common side effects of Dolutegravir film-coated tablets include Insomnia, Headache, Diarrhea, Nausea, Fatigue, Rash.

What does Dolutegravir film-coated tablets target?

Dolutegravir film-coated tablets targets HIV integrase and is a Integrase strand transfer inhibitor (INSTI).

Related